SAT0593 ANA TESTING IN THE (VERY) ELDERLY: EXPECTATION VERSUS REALITY
Authors: M. Luis, A. Carmo, R. Cunha, J. A. P. Da Silva, T. Santiago
Journal: Annals of the Rheumatic Diseases (2020)

Background: Antinuclear antibodies (ANA) are frequently used as a screening tool for systemic autoimmune rheumatic diseases (SARD), although they are also present in 10-15% of the adult healthy population. SARD have their peak incidence in the young/ middle-aged adult. As age progresses, the incidence of SARD decreases while the prevalence of ANA tends to increase, with some series reporting up to 30% prevalence in older ages 1 . Objectives: To determine the clinical significance and utility of ANA testing in a population over 85 years of age. Methods: We conducted a retrospective study of patients over the age of 85 who underwent ANA testing due to a SARD suspicion at our hospital autoimmunity laboratory, from 2011 to 2018. Justification for ANA request was collected from patient’s clinical records. Patients with pre-established diagnosis of SARD and patients with no justification given for ANA request were excluded from the analysis. ANA titer (positive ≥ 1:160) and cellular staining patterns were assessed by indirect immunofluorescence (Hep-2 cells). Results: Ages ranged from 85 to 98 years, with 58.8% being females. The prevalence of ANA in this population was 61.5%, mostly in lower titers (1:160 in 45.0%, 1:320 in 31.9%, 1:640 in 20.3% and 1:1280 in 2.7%). Dense fine speckled pattern was by far the most common cellular staining pattern (79.1%). A suspicion of SARD was the reported reason for ANA testing in 34,5% (n=296) of the 854 patients submitted to this test. The main clinical clues justifying SARD suspicion were: arthralgia/arthritis (11.9%), thrombocytopenia (10.0%), pancytopenia (10.0%), spotless fever (8.2%), interstitial lung disease (4.8%), pleural (6.1%) and pericardial (4.1%) effusion. Over a median follow-up of 1.0 year, 10 patients (3.4%) were diagnosed with a SARD, only one being an ANA-related disease: 5 cases of polymyalgia rheumatica, 2 cases of rheumatoid arthritis, 1 case of giant cell arteritis, 1 case of Sjogren syndrome and 1 case of sarcoidosis. In 60% of patients with a confirmed SARD, the main reason for suspicion was the presence of arthralgia/ arthritis. Positive ANA testing showed a 90.0% sensitivity and a 39.6% specificity for SARD. This translates into a positive predictive value of 5.0%. Conclusion: ANA are highly prevalent in elderly patients under SARD suspicion, while the incidence of SARD is very low, which explains the low positive predictive value of ANA testing. Interestingly, only one among the ten cases of SARD confirmed was indeed an ANA-related disease (Sjogren syndrome). References: [1]Selmi C, Ceribelli A, Generali E, et al. Serum antinuclear and extractable nuclear antigen antibody prevalence and associated morbidity and mortality in the general population over 15 years. Autoimmun Rev . 2016;15(2):162–166. doi:10.1016/j.autrev.2015.10.007 Disclosure of Interests: Mariana Luis: None declared, Anália Carmo: None declared, Rosário Cunha: None declared, José Antonio P. da Silva Grant/research support from: Pfizer, Abbvie, Consultant of: Pfizer, AbbVie, Roche, Lilly, Novartis, Tânia Santiago: None declared